Cost-Effectiveness of Adjuvant Immunotherapy With Cytokine-Induced Killer Cell for Hepatocellular Carcinoma Based on a Randomized Controlled Trial and Real-World Data
BackgroundStudies using data from randomized controlled trials (RCTs) and real-world data (RWD) have suggested that adjuvant cytokine-induced killer (CIK) cell immunotherapy after curative treatment for hepatocellular carcinoma (HCC) prolongs recurrence-free survival (RFS) and overall survival (OS)....
Saved in:
Main Authors: | , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/f7e177e3271a479b9a5a635e8afc0062 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!